HF
ORMP icon

HRT Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

HRT Financial’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93K Sell
27,498
-18,593
-40% -$63.1K ﹤0.01% 3363
2025
Q4 		$131K Buy
+46,091
New +$119K ﹤0.01% 2738
2024
Q1 		– Sell
-11,165
Closed -$25K – 2875
2023
Q4 		$25K Buy
+11,165
New +$23.8K ﹤0.01% 2020
2023
Q2 		– Sell
-45,035
Closed -$98K – 3033
2023
Q1 		$98K Buy
+45,035
New +$143K ﹤0.01% 2063
2022
Q1 		– Sell
-64,198
Closed -$916K – 3650
2021
Q4 		$916K Buy
+64,198
New +$1.34M 0.01% 1215

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HRT Financial's ORMP Position: Q1 2026 in Review

HRT Financial reduced its Oramed Pharmaceuticals (ORMP) stake by 40% in Q1 2026, selling an estimated $63.1K and leaving 27,498 shares worth $93K. The position accounts for ﹤0.01% of the portfolio, ranked #3363.

HRT Financial first reported a position in ORMP in Q4 2021 and has held it in 5 quarters since. The position peaked at $916K in Q4 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • HRT Financial held 27,498 shares of Oramed Pharmaceuticals worth $93K as of Q1 2026.
  • HRT Financial sold 18,593 Oramed Pharmaceuticals shares in Q1 2026, an estimated $63.1K.
  • Oramed Pharmaceuticals made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3363 holding.
  • HRT Financial first reported a position in Oramed Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • HRT Financial's Oramed Pharmaceuticals position peaked at $916K in Q4 2021.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.